Oct 6, 2026 07:35AM
Sep 29, 2026 07:30AM
Sep 1, 2026 06:00PM
Aug 27, 2026 06:00PM
Aug 20, 2026 07:30AM
Aug 6, 2026 06:30AM
May 27, 2026 06:00PM Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
Mar 17, 2026 07:30AM
Mar 17, 2026 07:30AM
Feb 18, 2026 07:30AM
Dec 18, 2025 07:30AM
Oct 30, 2025 07:30AM
Aug 7, 2025 07:30AM
Aug 4, 2025 04:30PM Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
Jul 31, 2025 04:30PM
Mar 26, 2025 07:30AM
Oct 15, 2024 08:30AM
Feb 29, 2024 07:30AM
Oct 16, 2023 07:30AM
Oct 10, 2023 04:45PM
Oct 6, 2022 06:12PM Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
Aug 11, 2022 07:30AM
Mar 29, 2022 07:36AM
Mar 24, 2022 07:30AM
Nov 8, 2021 10:00AM
Sep 23, 2021 07:30AM
May 14, 2021 07:30AM
Mar 1, 2021 07:04PM Thérapeutique Knight annonce le lancement commercial canadien de IBSRELA(MC) — un nouveau traitement innovant du syndrome de côlon irritable avec constipation
Sep 21, 2020 05:01PM
Sep 21, 2020 05:01PM
Aug 25, 2020 07:33AM
Aug 25, 2020 07:30AM
Aug 25, 2020 07:30AM
Apr 17, 2020 07:30AM
Nov 25, 2019 04:15PM Profound Medical Announces Health Canada Approval of TULSA-PRO®
Jun 26, 2019 08:30AM
Jun 25, 2019 08:30AM
Jun 18, 2019 05:00PM
Apr 4, 2019 08:45AM
Mar 14, 2019 08:30PM
Jan 11, 2019 08:03AM
Jan 11, 2019 08:00AM Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®
Nov 8, 2018 06:00AM
Nov 7, 2018 04:05PM
Sep 24, 2018 04:36PM
Aug 9, 2018 09:49AM
Aug 9, 2018 06:00AM
Jul 31, 2018 04:55PM
Jul 31, 2018 04:13PM Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership
Jul 31, 2018 04:12PM

333,568 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All